Log in to search using one of your social media accounts:

 

Bayer wins FDA nod for connected MS auto-injector
Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector. The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer and share data with their healthcare team. Get the full story at our sister site, Drug Delivery Business News. The post Bayer wins FDA nod for connected MS auto-injector a...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Bayer AG Source Type: news

Medical News Today: MS: Treating earliest signs reduces risk of diagnosis, relapse
Researchers suggest treating the earliest signs of multiple sclerosis with interferon beta-1b could reduce the risk of diagnosis and reduce relapse rate. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 11, 2016 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Extavia (Interferon Beta-1b Kit) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 20, 2016 Category: Drugs & Pharmacology Source Type: news

interferon beta-1b (Betaseron, Extavia)
Title: interferon beta-1b (Betaseron, Extavia)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/15/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 15, 2016 Category: Drugs & Pharmacology Source Type: news

BENEFIT 11: No new safety signals with interferon beta-1b
NEW ORLEANS – The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized, placebo-controlled BENEFIT trial... (Source: Clinical Neurology News)
Source: Clinical Neurology News - March 2, 2016 Category: Neurology Source Type: news

BENEFIT 11: No new safety signals with interferon beta-1b
NEW ORLEANS – The long-term safety of interferon beta-1b for the treatment of multiple sclerosis is well established, and 11-year outcomes from the randomized, placebo-controlled BENEFIT trial... (Source: Family Practice News)
Source: Family Practice News - March 2, 2016 Category: Primary Care Source Type: news

Bayer wins PMA for Betaconnect electronic autoinjector
Bayer (ETR:BAYN) said Monday it won FDA premarket approval for its Betaconnect electronic autoinjector for treating relapsing-remitting multiple sclerosis patients on the drug Betaseron. The Betaconnect is the 1st and only electronic autoinjector if its kind to treat RRMS, Whippany, N.J.-based Bayer said. “Bayer has a long legacy of supporting and providing services for the RRMS community. Betasaron was the 1st disease-modifying therapy approved by the FDA to treat RRMS patients, and today we are pleased to offer the 1st and only electronic auto injector for those living with the disease,” Bayer neurology ...
Source: Mass Device - October 1, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Drug Pumps Food & Drug Administration (FDA) Neurological Bayer HealthCare Source Type: news

Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector In Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
Bayer HealthCare has announced U.S. Food and Drug Administration (FDA) approval of BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will be available exclusively to BETASERON (interferon beta-1b) patients beginning in early 2016. (Source: Medical Design Online News)
Source: Medical Design Online News - September 28, 2015 Category: Medical Equipment Source Type: news

AAN round up
A reviews of presentations from last month's American Academy of Neurology meeting. Includes daclizumab, 11 year data on interferon beta-1b, the negative fingolimod in primary progressive MS trial, anti-LINGO-1, biotin - plus stem cells, salt, obesity and marriage. National MS Society (USA) Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - May 3, 2015 Category: Neurology Source Type: news

Efficacy of Interferon Beta-1b in Delaying the Onset of MSEfficacy of Interferon Beta-1b in Delaying the Onset of MS
Does early treatment with interferon beta-1b improve long-term outcomes for patients presenting with clinically isolated syndrome? Therapeutic Advances in Neurological Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Long-Term Results Underscore Value of Early MS Treatment Long-Term Results Underscore Value of Early MS Treatment
An 11-year follow-up of patients with MS treated with interferon beta-1b in the BENEFIT trial shows continued improved outcomes among those treated early. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - November 4, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Pregnancy and beta interferon
A report of the Betaseron Pregnancy Registry found that the 99 women who took beta interferon 1b (Betaferon / Betaseron) whilst pregnant found that instances of spontaneous abortion, stillbirth or birth abnormalities were no different than would be expected in the general population. The small sample size prevents definitive conclusions. MSIF Pregnancy - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - May 19, 2014 Category: Neurology Source Type: news

Betaseron (Interferon beta-1b) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 6, 2013 Category: Drugs & Pharmacology Source Type: news

Interleukin 17F Level And Interferon Beta Response In Patients With Multiple Sclerosis
JAMA Neurology Study Highlights A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universität, Düsseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis. (Online First) Serum samples were analyzed with an immunoassay from 239 randomly selected patients treated with interferon beta-1b, 250 micrograms, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 6, 2013 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news